Background and objective-Lithium has occasionally been reported to cause symptomatic sinus node bradyarryhthmias. The prevalence and mechanism of these arrhythmias during long-term treatment are unknown. The aims of this study were (a) to evaluate the systemic effects of lithium treatment on cardiac conduction in individuals who were free from cardiovascular disorders; (b) to assess the prevalence of lithium treatment in a group of patients with pacemakers; and (c) to evaluate the interaction between the parasympathetic limb of the autonomous nervous system and the sinus node cells during long-term lithium treatment.
Abstract
Background and objective-Lithium has occasionally been reported to cause symptomatic sinus node bradyarryhthmias. The prevalence and mechanism of these arrhythmias during long-term treatment are unknown. The aims of this study were (a) to evaluate the systemic effects of lithium treatment on cardiac conduction in individuals who were free from cardiovascular disorders; (b) to assess the prevalence of lithium treatment in a group of patients with pacemakers; and (c) to evaluate the interaction between the parasympathetic limb of the autonomous nervous system and the sinus node cells during long-term lithium treatment.
Patients and methods-45 patients who had been treated with lithium for >12 months were investigated in a long-term electrocardiography study. Only patients without cardiovascular disease, or concomitant chronotropic medication, or metabolic disorders known to cause rhythm disturbances were included. An age-stratified population was used as a reference group. 21 patients also underwent analysis of carotid sinus pressure and sinus cycle length before and after atropine to clarify whether neural mechanisms were involved. The prevalence of lithium treated patients was determined in 650 patients with pacemakers. Results-(a) Signs of moderate sinus node dysfunction (sinus arrest > I5 s, m mum heart rate <50 beats/min) were found in 56% and 78% respectively in the lithium-treated group compared with 30% and 30% respectively in the reference group (p < 0.01). Severe sinus node dysfunction was equally common in both groups. (b) The prevalence of chronic lithium treatment in the pacemaker population was 0'46%. (c) Sinus cycle variations were abnormal in the basal state in three (14%) patients and in 11 (52%) patients after atropine despite signs of intact and normal parasympathetic innervation. Conclusions-Depressed sinus node function was significantly more common in a lithium-treated population than in an age-stratified reference group. Clinically significant dysfunction, however, was uncommon. The function of the sinus node and its parasympathetic innervation were evaluated in a subset of the study group. The sinus cycle variations were assessed during one minute electrocardiographic recordings at a paper speed of 50 mm/s. The patients were requested to close their eyes and relax as much as possible while breathing at a normal rate and depth. The sinus cycle variations were calculated according to previously described methods.'819 The range of variation was expressed as a percentage of mean sinus cycle length, and the maximal difference between any two consecutive sinus cycle lengths (the maxdelta) was expressed in ms.
The observed values were compared with age-stratified reference values from 75 healthy subjects. 9 Carotid sinus pressure was then applied for 10 seconds twice on each side after carotid bruits had been excluded by auscultation. The maximal sinus cycle length during carotid sinus pressure was measured and compared with the mean of five sinus cycle lengths measured immediately before carotid sinus pressure at a paper speed 50 mm/s. Atropine was then given as an intravenous bolus injection of 0 04 mg per kg body weight over 30 seconds. After three minutes a new one minute recording for analysis of sinus cycle variation was obtained and carotid sinus pressure was then reapplied.
PACEMAKER POPULATION STUDY
We assessed the prevalence of patients on continuous (>12 months) lithium treatment by reviewing records from our pacemaker population. During a five year period 650 patients from a catchment area of 650 000 inhabitants had a permanent pacemaker implanted because of symptomatic bradyarrhythmias.
STATISTICAL ANALYSIS
Data are given as mean (SD) unless stated otherwise. The unpaired Students' t test was used to determine differences between groups and X2 analysis was used to test for differences in proportions. A probability of <0 05 was considered statistically significant.
The prospective part of this study was approved by the local ethics committee and patients gave their informed consent. Table 2 shows the clinical characteristics of the patients. All the patients had therapeutic or sub-therapeutic lithium concentrations in serum. Two patients with subtherapeutic lithium concentrations (0-3 and 0 4 mmol/l, therapeutic range 0-5-13 mmol/l) were included because the suboptimal serum concentrations had a good clinical effect. One patient with a slightly raised concentration of thyroid stimulating hormone was included because this spontaneously became normal four weeks later. One patient had signs of a moderate kidney dysfunction. All patients had normal serum potassium concentrations.
LONG-TERM ECG
Five patients were excluded from analysis because of unsatisfactory electrocardiographic recording quality. Thus 45 patients were included for final evaluation. Table 3 shows the prevalence of sinus node dysfunction as recorded on a long-term electrocardiogram in the lithium treated population. During the night the lowest heart rate was 33 beats/min and during the day it was 37 beats/min. The maximum sinus pause was 1-7 s during the day and 2 1 s during the night. In 33 patients (73%) the lowest heart rate occurred during day time whereas in nine patients it occurred during the night. In three patients there was no difference between day and night. No symptoms related to bradycardia were noted during the recording period. The mean age for the nine patients with heart rates below 40 beats/min or sinus pauses >1-5 s was 52-3 years; this was not significantly different from , and the remaining patient had both increased variation range and maxdelta, which is highly suggestive of sinus node dysfunction. 19 Carotid sinus pressure (n = 20) induced a mean maximal increase of 19% in the sinus cycle length (SD 12%; 5-51%). The maximum increase in any one patient was 394 ms; however, no sinus cycle length exceeded 1-3 s. Atropine induced a mean increase in heart rate of 30 beats/min (to a mean heart rate of 98 beats/min) corresponding to an increase of +45% (SD 9 beats/min; 15-53 beats/min). Carotid sinus pressure induced a mean increase of 2-8% after atropine, indicating almost complete vagolysis. In conjunction with this observation maxdeltas were decreased in all patients. However, the variation range was reduced to the expected degree in only 10 of the patients, while the remaining 11 showed a greater variation range after atropine than was expected.
PREVALENCE OF LITHIUM TREATMENT IN PATIENTS 'WITH PACEMAKERS
Three patients on long-term lithium treatment, a prevalence of 0-46%, were found in our pacemaker population, corresponding to an annual incidence of 0 05%. These were two women and one man aged 56, 64, and 72 years respectively. All patients had been treated with lithium for between 10 and 30 years. They all had therapeutic serum concentrations of lithium when cardiac symptoms were present. In all patients, signs of sinus node disease with heart rates of 28-45 beats/min and pauses of between 2-5 and 3-8 s were registered. In one patient an electrophysiological study was performed after lithium had been discontinued: it showed signs of persistent impairment of sinus node function. All three patients were given permanent pacemakers and became free of symptoms.
Discussion
The results from the present study indicate that depressed sinus node function was significantly more common in a lithium-treated population than in an age-stratified reference group. Clinically significant dysfunction, however, seems to be uncommon because we found a prevalence of only 0-46% of lithium treatment in a pacemaker population. Finally the effect of lithium on the sinus node seems to be intrinsic and not the result of increased parasympathetic tone. Tilkian et al20 studied 12 patients by 12 lead electrocardiography, an exercise test, and 24 h electrocardiographic recording before and 6-14 days after the start of lithium therapy. Though they observed slight chronotropic incompetence on exercise during lithium treatment they did not find any signs of sinus node dysfunction during 24 h ECG monitoring. It could be that the patients were studied too soon after the start of lithium treatment. In most of the case reports describing sinus node dysfunction during lithium treatment the patients had been treated for much longer. We only studied patients who had taken lithium for at least 12 months.
Hagman et al7 used 12 lead electrocardiography and carotid message to study 97 consecutive patients on long-term lithium treatment. Prolonged asystole (>3 s) owing to sinus node dysfunction or high grade atrioventricular block was seen during carotid massage in three symptom free patients, and was considered to be caused by lithium treatment. Whether asystole of >3 s during carotid massage in otherwise symptom free individuals indicates the presence of a conduction system disorder is controversial. Berglund et al reported on nine healthy individuals, three of whom had asystole of more than 3 s during carotid pressure.21 These subjects had completely normal Holter recordings and remained symptom free over a three year follow up. Bucht et al prospectively studied, with 12 lead electrocardiogram, 53 patients before and 4-12 months after the start of lithium treatment.22 Except for a significant decrease in resting heart rate during lithium treatment no signs of sinus node dysfunction were reported. The low sensitivity of the 12 lead electrocardiogram in detecting sinus node dysfunction might explain these results.
Though we found that in a lithium treated population sinus node dysfunction was about twice as common as expected we did not detect an increased prevalence of clinically significant dysfunction. Thus, severe sinus node disease in association with lithium treatment is probably uncommon: this is reflected by the low prevalence (<0 5%) of lithium treated patients in the pacemaker population. The hypothesis that symptomatic sinus node dysfumction could be underestimated among lithium-treated patients is therefore unlikely. It seems reasonable to postulate that the effect of lithium on the sinus node might only become clinically important in patients with latent sinus node dysfunction. We reviewed published reports on lithium-induced sinus node dysfunction in patients not taking concomitant chronotropic medication and without lithium intoxication (table 1) . We found 16 case reports and most of the patients showed complete or partial regression of the conduction disorder after lithium treatment stopped. Latent sinus node disease was suspected or confirmed in only three cases. It thus seems that lithium is able to induce clinically significant but reversible dysfunction in individuals with an otherwise normal sinus node.
None the less a pre-existing or latent sinus node disturbance may predispose to clinically important sinus node disease if lithium treatment is started. This suggestion is supported by the fact that patients who had sinus node dysfunction during lithium treatment including our own three patients were significantly older (63 (7) years) than our reference study population. This age group is also more typical of patients with clinical signs of sinus node disease.23
MECHANISM
The mechanism by which lithium depresses sinus node function is not fully understood. Animal experiments indicate that lithium depresses the intracellular potassium concentration. In addition lithium replaces intracellular calcium.24 These disturbances seem to induce various electrophysiological changes including a decrease of the depolarisation rate and reduced electrical impulse propagation. 25 In our study carotid sinus pressure showed the sinus node depolarisation rate, but not to the extent where it became abnormal. This implies intact innervation and absence of carotid sinus hypersensitivity. Absence of such hypersensitivity is contrary to the suggestion of Hagman et al. 7 The relative response to atropine resembled the 46% increase observed by Alboni et al 26 though their 20 healthy subjects had a slightly higher basic heart rate (76 v 68 beats/min), and reached a higher rate after atropine (111 v 98 beats/min). These results are also consistent with intact and normal parasympathetic innervation. Furthermore, they are consistent with the experimental data showing depolarisation at an increased time constant. It has also been suggested that lithium might decreast the sensitivity of the sinus node to sympathetic stimulation.27 Because the functional state after atropine reflects an unopposed sympathetic influence, the observed "normal" response to this drug in our study implies that the f, receptor sensitivity was unimpaired in our patients. The fact that episodes of bradycardia were more common during daytime-that is, they had non-circadian pattern despite an intact parasympathetic system-adds additional support to findings from animal data suggesting that lithium acts on the sinus node itself and not its nerve supply.8 Our data suggest that longterm lithium treatment changes the ionic milieu within the spontaneously depolarising sinus node cells even at therapeutic concentrations. It is not known whether or not a single ionic current is responsible for the depolarisation of the sinus node cells. Interaction between lithium and several currents such as IK, ICa, the Na/Ca exchange current, and a N/K pump current might lead to the observed results.28
LIMITATIONS OF THE STUDY
The reference group used in this study was not individually matched to the study group. Instead we used an age stratified reference population from another hospital.17 The proportion of females was higher in the study group than in the reference population. Though these groups were not strictly comparable, we do not consider that this significantly influenced our results. The study population was screened for absence of cardiovascular disorders and was not taking cardioactive drugs. The present results should be applied only to patients meeting these criteria.
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